Catalyst Wire Dossier Catalyst Wire Dossier

GBP510

SARS-CoV-2 recombinant protein nanoparticle vaccine adjuvanted with AS03 · SK Bioscience Co., Ltd.
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for GBP510, covering 2022-05-10 to 2024-10-16. Get the full timeline:

Most recent: Clinical Trial Update: Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older [Phase 3]

See pricing